Serum uric acid and multiple sclerosis

  title={Serum uric acid and multiple sclerosis},
  author={Stefano Sotgiu and Maura Pugliatti and Alessandra Sanna and Alessandra Sotgiu and M. L. Fois and Giannina Arru and Giulio Rosati},
  journal={Neurological Sciences},
Abstract. Several studies indicate that patients with multiple sclerosis (MS) have low serum levels of the endogenous antioxidant uric acid (UA), although it has not been established whether UA is primarily deficient or secondarily reduced due to its peroxynitrite scavenging activity. We measured serum urate levels in 124 MS patients and 124 age- and sex-matched controls with other neurological diseases. In addition, we compared UA levels when MS patients were stratified according to disease… 

Assessment of Serum Uric Acid Levels in Multiple Sclerosis during Disease-Modifying Treatment

Data suggest that UA concentration is lower in MS patients than in control group, and it seems that low uric acid levels indicate patients with a higher risk of disease progression.

Serum uric acid levels in multiple sclerosis patients inversely correlate with disability

This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score, which is associated with clinical relapse in multiple sclerosis patients.

Serum uric acid levels in patients with multiple sclerosis: a meta-analysis

The study suggests that UA is relevant to MS, and whether the administration of UA levels by inosine might be considered as a novel treatment strategy for MS is needed.

Uric acid: a potential biomarker of multiple sclerosis and of its disability

The findings support the importance of serum UA as a biomarker of MS disability and progression and should be specifically designed to evaluate the importance in the different stages of MS and in relation to distinct therapeutic strategies.

Serum Uric Acid Levels in Patients with Relapsing-Remitting Multiple Sclerosis

Serum UA levels did not correlate with clinical activity, EDSS score and disease duration either in relapse or remitting or both of them, and suggests serum uric acid levels may affect neither pathogenesis of MS nor activity of disease.

Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis.

  • G. Toncev
  • Medicine, Biology
    Vojnosanitetski pregled
  • 2006
The results suggested that the treatment approaches based on the elevation of serum uric acid levels might prove beneficial for some MS patients.

Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment

Although the authors do not know exactly whether and how UA is involved in MS pathogenesis, the data suggest that UA might reflect disease activity or treatment response in MS.

Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis

The results support the significance of UA in the pathogenesis of multiple sclerosis and suggest CSF UA concentrations may not be a reliable marker of disease activity in MS since its concentration is dependent on leakage of UA molecules from serum through the damaged BBB and the balance between consumption/production within the central nervous system (CNS).

Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients

The findings suggest that low urate levels could be of significance in predominantly inflammatory phases of MS even at the early stage and mainly in females.

The Correlation between Uric Acid Levels and Amyotrophic Lateral Sclerosis

Serum UA levels were inversely correlated with the disease “course factors” in the ALS male patients, and the elevation of serum UA concentration in ALS patients may be related to oxidative stress.



Uric acid levels in sera from patients with multiple sclerosis

It is suggested that serum UA might serve as a possible marker of disease activity in MS and provide support to the potential beneficial therapeutic effect of radical-scavenging substances in MS.

Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis

Investigating serum UA changes during open-label treatment of relapsing MS with GAA found increasing UA, a natural inhibitor of free radicals, may represent a mechanism of action of glatiramer acetate in MS.

Cerebrospinal Fluid Nitrate Levels in Patients with Multiple Sclerosis

CSF and plasma nitrate levels did not correlate with age at onset and duration of the disease in the patient group, suggesting that measurement of CSF levels of nitrate is not a marker of the activity of MS.

Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins

Observations were extended to 132 sets of twins with one sibling affected by multiple sclerosis and found that in blood of both mono- and dizygotic twins the uric acid levels were lower in the twin with the disease than in the healthy twin.

Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis.

Uric acid was increased and glutathione correspondingly decreased in plaques; alpha-tocopherol was lowest in plaque and highest in distant white matter in all cases, providing evidence supporting the involvement of free radicals in multiple sclerosis.

Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis.

Uric acid treatment was found to have strong therapeutic effects in a dose-dependent fashion and diminish clinical signs of a disease resembling EAE in interferon-gamma receptor knockout mice, raising the possibility that hyperuricemia may protect against MS.

Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker

Capillary electrophoresis analysis of nitrite and nitrate in CSF could provide a clinically useful way to determine disease activity in MS and is supportive of NOS induction in MS.

Changes in nitrite and nitrate (NO2 −/NO3 −) levels in cerebrospinal fluid of patients with multiple sclerosis

Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease

The findings that the allantoin/UA ratios were significantly higher in CLD than non-CLD infants not only in plasma but also in BALF, and that the intergroup differences of this ratio in both plasma and BALF was more prominent in the latter half of the first week of life further confirm the previous speculation that oxygen radicals are involved in the development of neonatal CLD.